Abstract
OBJECTIVE - To investigate renal elimination of the adipokine fibroblast growth factor 21 (FGF21) by determining circulating FGF21 levels in patients on chronic hemodialysis (CD) as compared with control subjects with a glomerular filtration rate (GFR) >50 ml/min. RESEARCH DESIGN AND METHODS- FGF21 was determined by enzyme-linked immunosorbent assay in control (n = 60) and CD (n = 60) patients and correlated to clinical and biochemical measures of renal function, glucose and lipid metabolism, and inflammation in both groups. RESULTS- Median serum FGF21 levelswere >15-foldhigherinCDpatients(3,710.6ng/ l) than in subjects with a GFR >50 ml/min (201.9 ng/l) (P < 0.001). Furthermore, serum creatinine positively and GFR negatively predicted FGF21 concentrations in multiple regression analyses in control subjects (P < 0.05). CONCLUSIONS - FGF21 serum levels increase in CD patients and are related to markers of renal function in control subjects. © 2009 by the American Diabetes Association.
Cite
CITATION STYLE
Stei, S., Bachmann, A., Lossner, U., Kratzsch, J., Blüher, M., Stumvoll, M., & Fasshauer, M. (2009). Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care, 32(1), 126–128. https://doi.org/10.2337/dc08-1054
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.